Nintedanib (Vargatef®) indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy.
Rapid Review
| Commenced | Completed | Outcome |
| 02/01/2015 | 10/02/2015 | Full Pharmacoeconomic Evaluation Recommended |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 03/06/2015 | 25/03/2016 | Reimbursement not Recommended at the Submitted Price. |
February 2017
The HSE has approved reimbursement following confidential price negotiations.